Nucleus Genomics, a pioneering genetic testing and analysis company, announced the debut of its DNA analysis product, marking a significant milestone in democratizing personalized medicine.

Founder and CEO Kian Sadeghi stated, “The promise of the Human Genome Project has finally arrived.”

DNA holds crucial insights into health, yet the full potential remains untapped in healthcare. Nucleus Genomics aims to bridge this gap by providing comprehensive genetic risk assessments for diseases like type 2 diabetes and breast cancer. Customers who have previously undergone microarray genetic testing with older companies can now leverage Nucleus’ platform to gain deeper insights into their genetic predispositions. Nucleus enhances these assessments by integrating personal and lifestyle factors such as age, cholesterol levels, blood pressure, and BMI.

Moreover, Nucleus is introducing pre-orders for its premium clinical-grade whole-genome sequencing (WGS) service. This service will analyze a customer’s entire DNA set, offering unparalleled insights into their genetic makeup. These comprehensive WGS results will be available starting this summer.

Nucleus offers a yearly membership fee of $39, granting members access to new platform features and disease reports. Additionally, members can opt for the 30x WGS kit priced at $399.

Sadeghi emphasized, “Nucleus is combining the power of whole-genome sequencing with innovative genomic analyses, ushering in a new era of personalized medicine accessible to the public.”

Nucleus ensures the highest quality by sequencing all customer samples in the U.S. on Illumina’s NovaSeq X Plus, the latest high-throughput sequencing instrument. With CLIA certification and CAP accreditation for its WGS informatics laboratory in North Carolina, Nucleus guarantees clinical-grade sequencing results.

Furthermore, Nucleus provides access to SteadyMD, an independent network of doctors and genetic counselors, to assist customers in understanding their WGS results and their implications.

Sadeghi highlighted Nucleus’ commitment to providing meaningful insights by offering polygenic risk scores (PRS) and identifying rare, high-impact variants. Nucleus continually updates disease risk scores based on individuals' changing lifestyles and emerging scientific discoveries.

Nucleus Genomics received $18 million in seed funding in 2022 from prominent venture capital firms, including Alexis Ohanian's Seven Seven Six and Peter Thiel’s Founders Fund, demonstrating confidence in its mission to leverage genomics for healthier lives.

In conclusion, Sadeghi affirmed, “Nucleus is the all-in-one genetic test, marking the realization of the Human Genome Project’s promise.”